Migratory cDC1 and cDC2 are potent cross-presenters of tumor antigens in LN.30 66 In our study, we observed higher frequencies of activated migratory cDC1 and migratory cDC2, which contained again a large proportion of CD64-expressing cells on BRAFi therapy. Here, FCGR1A is linked to neoplasm.